Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domain...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules & therapeutics Vol. 29; no. 3; pp. 282 - 289
Main Authors Kandeel, Mahmoud, Yamamoto, Mizuki, Tani, Hideki, Kobayashi, Ayako, Gohda, Jin, Kawaguchi, Yasushi, Park, Byoung Kwon, Kwon, Hyung-Joo, Inoue, Jun-ichiro, Alkattan, Abdallah
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society of Applied Pharmacology 01.05.2021
한국응용약물학회
Subjects
Original
약학
COVID-19
SARS-CoV-2
Fusion inhibitors
Antiviral drugs
Online AccessGet full text

Cover

Abstract A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARS-CoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.
AbstractList A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARS-CoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARS-CoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.
A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 μM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 μM). Peptide #2 inhibited the SARSCoV- 2 pseudovirus assay at IC50=1.49 μM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2. KCI Citation Count: 12
A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARS-CoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.
Author Park, Byoung Kwon
Kandeel, Mahmoud
Kwon, Hyung-Joo
Kawaguchi, Yasushi
Kobayashi, Ayako
Inoue, Jun-ichiro
Gohda, Jin
Alkattan, Abdallah
Tani, Hideki
Yamamoto, Mizuki
AuthorAffiliation 7 Senior Professor Office, The University of Tokyo, Tokyo 108-8639, Japan
5 Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
6 Department of Microbiology, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
3 Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
2 Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt
1 Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia
4 Department of Virology, Toyama Institute of Health, Toyama 939-0363, Japan
AuthorAffiliation_xml – name: 2 Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt
– name: 5 Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
– name: 6 Department of Microbiology, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
– name: 7 Senior Professor Office, The University of Tokyo, Tokyo 108-8639, Japan
– name: 1 Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia
– name: 3 Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
– name: 4 Department of Virology, Toyama Institute of Health, Toyama 939-0363, Japan
Author_xml – sequence: 1
  givenname: Mahmoud
  surname: Kandeel
  fullname: Kandeel, Mahmoud
  organization: Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia, Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt
– sequence: 2
  givenname: Mizuki
  surname: Yamamoto
  fullname: Yamamoto, Mizuki
  organization: Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
– sequence: 3
  givenname: Hideki
  surname: Tani
  fullname: Tani, Hideki
  organization: Department of Virology, Toyama Institute of Health, Toyama 939-0363, Japan
– sequence: 4
  givenname: Ayako
  surname: Kobayashi
  fullname: Kobayashi, Ayako
  organization: Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
– sequence: 5
  givenname: Jin
  surname: Gohda
  fullname: Gohda, Jin
  organization: Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
– sequence: 6
  givenname: Yasushi
  surname: Kawaguchi
  fullname: Kawaguchi, Yasushi
  organization: Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
– sequence: 7
  givenname: Byoung Kwon
  surname: Park
  fullname: Park, Byoung Kwon
  organization: Department of Microbiology, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
– sequence: 8
  givenname: Hyung-Joo
  surname: Kwon
  fullname: Kwon, Hyung-Joo
  organization: Department of Microbiology, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
– sequence: 9
  givenname: Jun-ichiro
  surname: Inoue
  fullname: Inoue, Jun-ichiro
  organization: Senior Professor Office, The University of Tokyo, Tokyo 108-8639, Japan
– sequence: 10
  givenname: Abdallah
  surname: Alkattan
  fullname: Alkattan, Abdallah
  organization: Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33424013$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002708651$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9UctuEzEUtVARTQtfgIS8hMUUv2Ycb5CiQNtIFaAmsLVsx05MJnawPUX5e5ym5bVgc-7inod9zxk4CTFYAF5idMFQR95qH7exL2ubLggiqAJ-AkYEobZhbExPwAgL3jUCs_EpOMv5G0Idx233DJxSyghDmI6AfO-ziXc27WF08KP9AS-H7GOAs7D22peY4Ge7K35pM1Qr5UMucD65nTfT-LUhUO_hQqWVLT6sYH0KnO_8piKB80EPwZfn4KlTfbYvHuY5-HL5YTG9bm4-Xc2mk5vGsLZrG-O4I4Jrh9hYcaQtEoIuFaHaYtq2Si8R7RjViDDtnCPUCIW54oagziBN6Dl4c_QNycmN8TIqfz9XUW6SnNwuZlJw3rUCV-67I3c36K1dGhtKUr3cJb9VaX-v_HsT_Lr63MkxEgzxthq8fjBI8ftgc5HbekXb9yrYOGRJGO_GjCF6oL76M-tXyGMDlSCOBJNizsk6aXxRpVZQo30vMZKHtuXvtuWh7QqHj9B_tI_2_1P9BCa6sR4
CitedBy_id crossref_primary_10_1021_acs_jmedchem_2c01229
crossref_primary_10_1038_s41392_021_00733_x
crossref_primary_10_1080_17460441_2022_2050693
crossref_primary_10_4062_biomolther_2022_037
crossref_primary_10_3390_ph15030282
crossref_primary_10_1016_j_mam_2022_101151
crossref_primary_10_3390_antibiotics10111294
crossref_primary_10_1093_pnasnexus_pgac198
crossref_primary_10_3390_vaccines10122089
crossref_primary_10_1016_j_mbs_2024_109144
crossref_primary_10_1080_0889311X_2024_2363756
crossref_primary_10_3389_fmicb_2021_817200
crossref_primary_10_3389_fphar_2022_1007527
crossref_primary_10_3390_vaccines9020178
crossref_primary_10_17816_CI2023231_1
crossref_primary_10_1007_s40267_022_00893_y
crossref_primary_10_3923_ijp_2024_1_10
crossref_primary_10_1039_D3CB00166K
crossref_primary_10_3389_fphar_2021_685161
crossref_primary_10_1016_j_idairyj_2023_105805
crossref_primary_10_3390_ijms24054401
crossref_primary_10_1016_j_antiviral_2022_105428
crossref_primary_10_1021_acsnano_2c09015
crossref_primary_10_1139_bcb_2021_0342
crossref_primary_10_1021_acs_analchem_4c05966
crossref_primary_10_1016_j_genrep_2022_101619
crossref_primary_10_1021_acs_jmedchem_3c01543
crossref_primary_10_3390_pr11020398
crossref_primary_10_3390_v15051171
crossref_primary_10_1002_pmic_202300257
Cites_doi 10.1016/j.antiviral.2008.10.001
10.1128/JVI.02433-13
10.1371/journal.ppat.1007236
10.1016/j.compbiolchem.2018.05.020
10.1038/s41563-018-0194-2
10.1002/jcp.30032
10.1016/j.cell.2020.02.052
10.1128/AAC.00827-09
10.1371/journal.pone.0096790
10.1126/science.aan0516
10.1016/j.ultrasmedbio.2018.10.003
10.1021/acs.jctc.8b01123
10.1002/jcc.20291
10.1155/2014/825039
10.1016/j.vetmic.2008.10.009
10.1038/s41591-020-0868-6
10.1126/sciadv.aav4580
10.1002/jcb.21790
10.1007/s40005-016-0253-0
10.1128/JVI.77.16.8801-8811.2003
10.1016/j.ejmech.2016.05.027
10.1016/j.virusres.2006.03.001
10.1016/j.virusres.2014.10.007
10.1016/j.lfs.2020.117627
10.1093/ije/dyaa033
10.1128/JVI.02499-09
10.1080/07391102.2020.1784291
10.1074/jbc.M111.317883
10.1371/journal.pone.0139652
10.1128/JVI.00635-20
10.1073/pnas.1711837115
10.1002/jmv.20095
10.1016/S0140-6736(04)15788-7
10.3390/v12060629
10.1016/bs.apcsb.2014.11.001
10.1371/journal.pcbi.1004494
10.1099/jgv.0.000991
10.1093/nar/gkt450
10.1128/JVI.01815-18
10.1016/j.jconrel.2006.12.022
10.4062/biomolther.2019.202
10.1038/nature17200
10.1038/ncomms4067
10.1016/j.cell.2020.04.035
ContentType Journal Article
Copyright Copyright © 2021, The Korean Society of Applied Pharmacology 2021
Copyright_xml – notice: Copyright © 2021, The Korean Society of Applied Pharmacology 2021
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.4062/biomolther.2020.201
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2005-4483
EndPage 289
ExternalDocumentID oai_kci_go_kr_ARTI_9776591
PMC8094075
33424013
10_4062_biomolther_2020_201
Genre Journal Article
GroupedDBID ---
23N
5-W
5GY
8JR
9ZL
AAYXX
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
DU5
EF.
F5P
HZB
JDI
KQ8
M48
OK1
PGMZT
RPM
NPM
7X8
5PM
ACYCR
ADRAZ
HYE
ID FETCH-LOGICAL-c4565-cf7f297bf048a70be0993da23be1355abd03643b024bfff23c9a17a7c206c0b23
IEDL.DBID M48
ISSN 1976-9148
IngestDate Sun Mar 09 07:53:36 EDT 2025
Thu Aug 21 13:58:56 EDT 2025
Fri Jul 11 05:33:55 EDT 2025
Thu Apr 03 06:58:29 EDT 2025
Tue Jul 01 04:15:29 EDT 2025
Thu Apr 24 23:05:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 3
Keywords COVID-19
SARS-CoV-2
Fusion inhibitors
Antiviral drugs
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4565-cf7f297bf048a70be0993da23be1355abd03643b024bfff23c9a17a7c206c0b23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2020.201
PMID 33424013
PQID 2476844035
PQPubID 23479
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9776591
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8094075
proquest_miscellaneous_2476844035
pubmed_primary_33424013
crossref_citationtrail_10_4062_biomolther_2020_201
crossref_primary_10_4062_biomolther_2020_201
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-05-01
PublicationDateYYYYMMDD 2021-05-01
PublicationDate_xml – month: 05
  year: 2021
  text: 2021-05-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Biomolecules & therapeutics
PublicationTitleAlternate Biomol Ther (Seoul)
PublicationYear 2021
Publisher The Korean Society of Applied Pharmacology
한국응용약물학회
Publisher_xml – name: The Korean Society of Applied Pharmacology
– name: 한국응용약물학회
References ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref42
ref41
ref22
ref44
ref21
ref43
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
References_xml – ident: ref21
  doi: 10.1016/j.antiviral.2008.10.001
– ident: ref8
  doi: 10.1128/JVI.02433-13
– ident: ref32
  doi: 10.1371/journal.ppat.1007236
– ident: ref18
  doi: 10.1016/j.compbiolchem.2018.05.020
– ident: ref14
  doi: 10.1038/s41563-018-0194-2
– ident: ref29
  doi: 10.1002/jcp.30032
– ident: ref11
  doi: 10.1016/j.cell.2020.02.052
– ident: ref12
  doi: 10.1128/AAC.00827-09
– ident: ref38
  doi: 10.1371/journal.pone.0096790
– ident: ref15
  doi: 10.1126/science.aan0516
– ident: ref31
  doi: 10.1016/j.ultrasmedbio.2018.10.003
– ident: ref30
  doi: 10.1021/acs.jctc.8b01123
– ident: ref36
  doi: 10.1002/jcc.20291
– ident: ref6
  doi: 10.1155/2014/825039
– ident: ref24
  doi: 10.1016/j.vetmic.2008.10.009
– ident: ref34
  doi: 10.1038/s41591-020-0868-6
– ident: ref40
  doi: 10.1126/sciadv.aav4580
– ident: ref5
  doi: 10.1002/jcb.21790
– ident: ref1
  doi: 10.1007/s40005-016-0253-0
– ident: ref2
  doi: 10.1128/JVI.77.16.8801-8811.2003
– ident: ref4
  doi: 10.1016/j.ejmech.2016.05.027
– ident: ref28
  doi: 10.1016/j.virusres.2006.03.001
– ident: ref39
  doi: 10.1016/j.virusres.2014.10.007
– ident: ref17
  doi: 10.1016/j.lfs.2020.117627
– ident: ref26
  doi: 10.1093/ije/dyaa033
– ident: ref35
  doi: 10.1128/JVI.02499-09
– ident: ref16
  doi: 10.1080/07391102.2020.1784291
– ident: ref42
  doi: 10.1074/jbc.M111.317883
– ident: ref33
  doi: 10.1371/journal.pone.0139652
– ident: ref43
  doi: 10.1128/JVI.00635-20
– ident: ref9
  doi: 10.1073/pnas.1711837115
– ident: ref27
  doi: 10.1002/jmv.20095
– ident: ref22
  doi: 10.1016/S0140-6736(04)15788-7
– ident: ref41
  doi: 10.3390/v12060629
– ident: ref37
  doi: 10.1016/bs.apcsb.2014.11.001
– ident: ref3
  doi: 10.1371/journal.pcbi.1004494
– ident: ref10
  doi: 10.1099/jgv.0.000991
– ident: ref7
  doi: 10.1093/nar/gkt450
– ident: ref13
  doi: 10.1128/JVI.01815-18
– ident: ref25
  doi: 10.1016/j.jconrel.2006.12.022
– ident: ref19
  doi: 10.4062/biomolther.2019.202
– ident: ref20
  doi: 10.1038/nature17200
– ident: ref23
  doi: 10.1038/ncomms4067
– ident: ref44
  doi: 10.1016/j.cell.2020.04.035
SSID ssj0067156
Score 2.3619123
Snippet A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 282
SubjectTerms Original
약학
Title Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit
URI https://www.ncbi.nlm.nih.gov/pubmed/33424013
https://www.proquest.com/docview/2476844035
https://pubmed.ncbi.nlm.nih.gov/PMC8094075
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002708651
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biomolecules & Therapeutics, 2021, 29(3), , pp.282-289
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaIqFeEIjXUloZxBGXZOysk1NVFVYtUhFiu6g3y3bsNtpV0ma7Evvvmck-YFHhwCU5xI9o7PH3jT2eYexddInMbK6EB7AC7Y1S5IhKAtfFIvPaKg90G_n8S_90pD5fZpdbbJUVdSnA6b2mHeWTGrWTwx-38yNUeOSvhwhH8IEuqjcT4kto70FC_lrb7AFCkyZNPVfrY4W-Trt0riliMGq5yhdhiP7WyC57KKUCskA2UGu7buN9hPRPv8rfgGrwmD1aMkx-vJgST9hWqJ8y87GaevLWnPMmclzZ-GBG-2T8rL6uHGp1y7-Sf0sZptxe2QpJIx8efxuKk-a7AO7m_KJzGUeg4_j3fHhTjfEJHBeeGa4Kz9ho8Oni5FQscysITxxO-KgjFNpF1GCrExeQKcrSgnQhRQpiXUkHlNIhhLsYI0hf2FRb7SHp-8SBfM526qYOLxl3CH65zdE2KktlfWkDQAFBZaGQCTbUY7CSnfHLwOOU_2Ji0AAh2Ztfsjcke3ykPfZ-XelmEXfj38Xf4qCYsa8Mxcum91Vjxq1Bq-DMIMftZwUWerMaM4NKRCcjtg7NbGpA0XmkwmnbYy8WY7judTUFekxvjO66AHW4-aWurrtA3TkFJ9TZq_-uucd2gXxoOgfL12znrp2FfSRBd-6gm9gH3e7UT-V7CJw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+of+New+Fusion+Inhibitor+Peptides+against+SARS-CoV-2+by+Targeting+the+Spike+S2+Subunit&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Kandeel%2C+Mahmoud&rft.au=Yamamoto%2C+Mizuki&rft.au=Tani%2C+Hideki&rft.au=Kobayashi%2C+Ayako&rft.date=2021-05-01&rft.pub=The+Korean+Society+of+Applied+Pharmacology&rft.issn=1976-9148&rft.eissn=2005-4483&rft.volume=29&rft.issue=3&rft.spage=282&rft.epage=289&rft_id=info:doi/10.4062%2Fbiomolther.2020.201&rft_id=info%3Apmid%2F33424013&rft.externalDocID=PMC8094075
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-9148&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-9148&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-9148&client=summon